Application of BMP9 protein in osteoclast function regulation
By regulating osteoclast function through the BMP9 protein, the problems of osteoporosis and fracture risk in the elderly have been addressed, achieving effective drug intervention.
Patent Information
- Application Number
- CN202410961063.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-15
AI Technical Summary
Current technologies have failed to effectively regulate osteoclast function, leading to an increased risk of osteoporosis and fractures in the elderly, and there is a lack of effective drug interventions.
By utilizing the BMP9 protein to regulate osteoclast function, osteoclast differentiation was inhibited and the expression of related markers was reduced through in vitro experiments, thereby preparing drugs for osteoporosis and fracture prevention in the elderly.
BMP9 protein directly inhibits osteoclast differentiation and reduces the expression of related markers, which is of great significance and has the potential to treat osteoporosis in the elderly and reduce the risk of fractures.
Smart Images

Figure CN118949011A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, relates to new uses of drugs, and specifically relates to the use of BMP9 protein in regulating osteoclast function. Background Art
[0002] Osteoporosis is a systemic bone disease characterized by low bone mass, damage to bone tissue microstructure, increased bone fragility, and susceptibility to fractures (Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis [J]. Am J Med, 1993, 94 (6): 646-650.). In 2001, the National Institutes of Health (NIH) defined it as a bone disease characterized by decreased bone strength and increased risk of fractures (NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference [J]. South Med J, 2001, 94 (6): 569-573.).
[0003] Osteoporosis can occur at any age, but is more common in postmenopausal women and elderly men. As the aging of my country's population intensifies, the prevalence of osteoporosis has risen rapidly and has become an important public health issue. The seventh national census showed that my country has 264 million people over the age of 60 and more than 190 million people over the age of 65, making it the country with the largest elderly population in the world. The national osteoporosis epidemiological survey showed that the prevalence of osteoporosis in people over the age of 50 was 19.2%, including 32.1% in women and 6.9% in men; the prevalence of osteoporosis in people over the age of 65 was 32.0%, including 51.6% in women and 10.7% in men. According to the above epidemiological data, the current number of osteoporosis patients in my country is about 90 million (China Center for Disease Control and Prevention, Chronic Non-communicable Disease Prevention and Control Center, Osteoporosis and Bone Mineral Disease Branch of the Chinese Medical Association. China Osteoporosis Epidemiological Survey Report (2018) [M]. Beijing: People's Medical Publishing House, 2021.).
[0004] Bones need to have sufficient rigidity and toughness to maintain their strength, bear external forces, and avoid fractures. To this end, bones are required to have a complete hierarchical structure, including the triple helix structure of type I collagen, non-collagenous proteins, and hydroxyapatite deposited therein. The integrity of bones is maintained by the repeated, spatiotemporally coupled bone resorption and bone formation processes, a process called bone remodeling. Bone remodeling is carried out by the basic multicellular unit (BMU) of bones composed of osteoblasts, osteoclasts, and osteocytes. Before adulthood, bones are constantly constructed, shaped, and remodeled. The positive balance between bone formation and bone resorption increases bone mass and reaches peak bone mass. In adulthood, bone remodeling is balanced to maintain bone mass. Thereafter, with increasing age, bone formation and bone resorption are in a negative balance, and an imbalance in bone remodeling causes bone loss. Mechanical stimulation and weight-bearing are conducive to maintaining bone remodeling, repairing bone micro-damage, and avoiding micro-damage accumulation and fractures. Osteocytes distributed around the Haversian canals (accounting for 90% to 95% of bone cells) can sense micro-injury and mechanical stimulation of bones, and directly communicate with neighboring bone cells, or with other bone cells through endocrine, autocrine and paracrine means. When mechanical stimulation changes or micro-injury penetrates the lamellar bone or microtubule system, it will induce the migration and differentiation of osteoclast precursors by affecting the signal transduction of osteocytes. Osteoclasts account for 1% to 2% of bone cells, are formed by differentiation of mononuclear macrophage precursors, and are responsible for bone resorption. The key regulatory steps of osteoclastogenesis include the binding of the receptor activator of nuclear factor κB ligand (RANKL) to the receptor activator of nuclear factor κB (RANK) on osteoclast precursor cells, activating the NF-κB signaling pathway and promoting osteoclast differentiation. Osteoclast bone resorption disorder is the basis of the pathogenesis of osteoporosis and malignant osteolytic bone disease. Summary of the invention
[0005] In order to solve the problems in the prior art, the present invention provides the use of BMP9 protein in regulating osteoclast function.
[0006] BMP9 protein (Bone morphogenetic protein 9, BMP9) is mainly secreted by hepatic stellate cells, can regulate sugar and lipid metabolism, and has high affinity receptors on hepatic macrophages. Chinese patent CN 115040638 A and journal literature report that BMP9 is associated with liver diseases, including non-alcoholic fatty liver disease (NAFLD), liver fibrosis and hepatocellular carcinoma (HCC) (Jiang QQ, Liu BB, Xu KS. New insights into BMP9 signaling in liver diseases. Mol Cell Biochem. 2021 Oct; 476(10): 3591-3600. doi: 10.1007 / s11010-021-04182-6. Epub 2021 May 21. PMID: 34019202.). In addition, it has been reported that BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma (HanY, Pan Q, Guo Z, DuY, ZhangY, LiuY, Zhao J, XuJ, Yang J, Ouyang D, Tang Y, Wang Q, Li Y, He J, Yang M, Chen H, Yang C, Yang X, You J, Chen Y, Ren M, Zhu Y, Xia J, Xiang T. BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma. Clin Transl Med. 2023May; 13(5): e1247. doi: 10.1002 / ctm2.1247. PMID: 37132170; PMCID: PMC10154878.).There are also literatures pointing out that hypothalamic BMP9 inhibits glucose production through the central PI3K / Akt / mTOR pathway (He Y, Zhang C, Luo Y, Chen J, Yang M, Li L, GuHF, Yang G, Zhang X. Hypothalamic BMP9 suppresses glucose production by centralPI3K / Akt / mTOR pathway. J Endocrinol. 2021Feb; 248(2): 221-235. doi: 10.1530 / JOE-19-0591. PMID: 33337347.); and BMP9 protects the pulmonary endothelium during inflammation-induced lung injury in mice (Li W, LongL, Yang X, Tong Z, Southwood M, King R, Caruso P, Upton PD, Yang P, Bocobo GA, NikolicI, Higuera A, Salmon RM, Jiang H, Lodge KM, Hoenderdos K, Baron RM, Yu PB, Condliffe AM, Summers C, Nourshargh S, Chilvers ER, Morrell NW. Circulating BMP9 Protects the Pulmonary Endothelium during Inflammation-induced Lung Injury in Mice. AmJ Respir Crit Care Med. 2021Jun 1;203(11):1419-1430.doi:10.1164 / rccm.202005-1761OC.PMID:33320799; PMCID:PMC8456542.).
[0007] The object of the present invention is achieved in that:
[0008] Use of BMP9 protein in preparing osteoclast function regulating drugs.
[0009] As a preferred embodiment, the BMP9 of the present invention is used in the preparation of a preparation or medicine for osteoporosis in the elderly.
[0010] Furthermore, the present invention provides an application of BMP9 in the preparation of an anti-fracture preparation or medicine for the elderly.
[0011] As a preference, the medicine is an injection.
[0012] Beneficial effects of the present invention
[0013] The present invention discloses the use of BMP9 protein in regulating osteoclast function. The present invention has found that BMP9 directly inhibits the differentiation of osteoclasts derived from BMMs in vitro, and osteoclast-related protein markers are reduced, which is of great significance for the treatment of osteoporosis in the elderly. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is the TRAP staining image of mature osteoclasts.
[0015] Figure 2 It is the statistical diagram of TRAP staining of mature osteoclasts.
[0016] Figure 3 This is a graph showing the expression of osteoclast-related marker proteins detected by Western Blot.
[0017] Figure 4 This is a graph showing the expression of osteoclast-related marker protein CTSK.
[0018] Figure 5 This is a graph showing the expression of osteoclast-related marker protein RANK.
[0019] Figure 6 This is a graph showing the expression of osteoclast-related marker protein TRAP. DETAILED DESCRIPTION
[0020] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them.
[0021] Based on the described embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0022] Unless otherwise defined, technical or scientific terms used herein shall have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs.
[0023] The words “include” or “comprising” and the like used in the specification and claims of the present invention mean that the elements or objects appearing before “include” or “comprising” include the features, wholes, steps, operations, elements and / or components listed after “include” or “comprising”, and do not exclude the existence or addition of one or more other features, wholes, steps, operations, elements, components and / or their collections.
[0024] The BMP9 protein sequence of the present invention is as follows: STGASSHCQK TSLRVNFEDI GWDSWIIAPK EYDAYECKGGCFFPLADDVT PTKHAIVQTL VHLKFPTKVG KACCVPTKLS PISILYKDDM GVPTLKYHYE GMSVAECGCR
[0025] Example 1
[0026] Primary culture of mouse osteoclasts:
[0027] Bone marrow cell induction method was used to induce differentiation of osteoclast-like cells: 6-week-old female BALB / C mice were treated by anesthesia and cervical dislocation, and the mice were soaked in 75% alcohol for 5 minutes. The femurs, tibias, and humeri of the mice were separated by aseptic blunt force. The tibias, femurs, and humeri were removed with scissors in a clean bench, and soaked and washed in PBS buffer. The epiphyseal ends at both ends were cut off, and the α-MEM complete medium was drawn with a sterile syringe to repeatedly flush the bone marrow cavity until it turned white, and the flushing fluid was collected in a sterilized centrifuge tube , centrifuged at 1000r / min for 5min, discarded the supernatant, resuspended the cells in α-MEM complete medium and inoculated in a 10cm culture dish, cultured in a cell culture incubator at 37℃, 5% CO2 for 24h, collected the suspended cells and centrifuged at 1000r / min for 5min, inoculated the obtained cells in a 96-well plate at a density of 104 / well, divided into three groups, each with five sub-wells; inoculated in a 6-well plate at a density of 106 / well, divided into three groups, each with 3 sub-wells:
[0028] A. Control group: The cells were stimulated with 30 ng / ml M-CSF for the first 3-4 days to induce bone marrow giant cells, and then 100 ng / ml RANKL was added for 6-7 days to induce osteoclast differentiation. The medium was changed every two days, and TRAP staining experiments were performed for verification.
[0029] B. BMP9 group 80ng / ml: 30ng / ml M-CSF was used to induce bone marrow giant cells in the first 3-4 days, and then 100ng / ml RANKL and 80ng / ml BMP9 were added for 6-7 days to induce osteoclast differentiation. The medium was changed every two days and TRAP staining experiment was performed for verification.
[0030] C. BMP9 group 160ng / ml: 30ng / ml M-CSF was used to induce bone marrow giant cells for the first 3-4 days, and then 100ng / ml RANKL and 160ng / ml BMP9 were added to culture for 6-7 days to induce osteoclast differentiation. The medium was changed every two days and TRAP staining experiment was performed for verification.
[0031] After the cell culture cycle is completed:
[0032] a. WB experiment was performed in 6-well plates to detect the expression of osteoclast markers RANK, TRAP, and CTSK.
[0033] b. TRAP staining of mature osteoclasts was performed in 96-well plates.
[0034] like Figure 1 As shown, after bone marrow mesenchymal stem cells were induced with MCSF and RANKL in the presence of different doses of BMP9 for 5 days, TRAP-positive multinuclear cells were identified by TRAP staining.
[0035] The statistical results of the number of TRAP-positive multinucleated cells after treatment with different doses of BMP9 are shown in Figure 2 shown.
[0036] Western Blot analysis of the expression levels of osteoclast function markers (TRAP, CTSK, RANK) after treatment with different concentrations of BMP9. Figure 3 shown.
[0037] The statistical results of the expression level of the osteoclast function marker CTSK gene after treatment with different concentrations of BMP9 are shown in Figure 4 shown.
[0038] The statistical results of the expression level of the osteoclast function marker RANK gene after treatment with different concentrations of BMP9 are shown in Figure 5 shown.
[0039] The statistical results of the expression level of the osteoclast functional marker TRAP gene after treatment with different concentrations of BMP9 are shown in Figure 6 shown.
[0040] Although the present invention has been disclosed as above with preferred embodiments, it is not intended to limit the present invention. A person with ordinary knowledge in the technical field to which the present invention belongs may make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention shall be determined by the definition of the claims.
Claims
1. Use of BMP9 protein in the preparation of osteoclast function regulating drugs.
2. Application of BMP9 in the preparation of preparations or drugs for osteoporosis in the elderly.
3. Application of BMP9 in the preparation of anti-fracture preparations or drugs for the elderly.
4. The use according to any one of claims 1 to 3, characterized in that: The medicine is an injection.
